<DOC>
	<DOCNO>NCT00286247</DOCNO>
	<brief_summary>A maximum 60 subject enrol trial . It non-randomized , open label , single center study . All subject undergo INGN 201 injection IV chemotherapy : doxorubicin docetaxel . This do first 2 day 3-week cycle . After completion 4 6 cycle , subject either proceeds surgery tumor respond therapy , go study tumor response .</brief_summary>
	<brief_title>Study Determine Efficacy Safety Docetaxel Doxorubicin With INGN 201 Locally Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Documented late stage breast cancer : stage III AB ( exclude inflammatory breast carcinoma ) localize stage IV breast cancer Male female 18 year old Adequate bone marrow , liver , kidney function</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2008</verification_date>
</DOC>